 |
6 Diseases |  |
0 Trials |
|
0 Trials |  |
25 News |  |
- Venclexta (venetoclax) / Roche, AbbVie
CD3xCD19 Dart Treatment Is Efficient in Venetoclax Resistant CLL and Reverses T Cell Dysfunction (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_4235;
Furthermore, it shows that venetoclax resistant CLL can still be efficiently targeted by T cells, in a non-apoptotic fashion . These results imply that T cell mediated therapy could be used alongside venetoclax.
- | duvortuxizumab (MGD011) / MacroGenics
Trial termination: A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies (clinicaltrials.gov) - Dec 21, 2018
P1, N=59, Terminated, Sponsor: Janssen Research & Development, LLC
These results imply that T cell mediated therapy could be used alongside venetoclax. Completed --> Terminated; Recent advances in the treatment of B cell malignancies resulting in new treatments being approved for marketing and many others in late stage development
- | duvortuxizumab (MGD011) / MacroGenics
Trial completion, Trial completion date, Trial primary completion date: A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies (clinicaltrials.gov) - Sep 25, 2018
P1, N=59, Completed, Sponsor: Janssen Research & Development, LLC
Completed --> Terminated; Recent advances in the treatment of B cell malignancies resulting in new treatments being approved for marketing and many others in late stage development Active, not recruiting --> Completed | Trial completion date: Jan 2021 --> Jul 2018 | Trial primary completion date: Jan 2020 --> Jul 2018
- || duvortuxizumab (MGD011) / MacroGenics
Enrollment change: A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies (clinicaltrials.gov) - Nov 14, 2017
P1, N=59, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed | Trial completion date: Jan 2021 --> Jul 2018 | Trial primary completion date: Jan 2020 --> Jul 2018 N=220 --> 59
- duvortuxizumab (MGD011) / MacroGenics
Enrollment change, Trial withdrawal: Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma (clinicaltrials.gov) - Oct 9, 2017
P1b, N=0, Withdrawn, Sponsor: Janssen Research & Development, LLC
N=220 --> 59 N=64 --> 0 | Suspended --> Withdrawn
- || duvortuxizumab (MGD011) / MacroGenics
Enrollment closed: A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies (clinicaltrials.gov) - Sep 18, 2017
P1, N=220, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
N=64 --> 0 | Suspended --> Withdrawn Recruiting --> Active, not recruiting
- || duvortuxizumab (MGD011) / MacroGenics
Trial primary completion date: A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies (clinicaltrials.gov) - Apr 25, 2017
P1, N=220, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2017 --> Jan 2020
- || duvortuxizumab (MGD011) / MacroGenics
Phase classification, Enrollment change: A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies (clinicaltrials.gov) - Oct 19, 2016
P1, N=221, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Oct 2017 --> Jan 2020 Phase classification: P2 --> P1 | N=155 --> 221
- | duvortuxizumab (MGD011) / MacroGenics
Trial suspension: Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma (clinicaltrials.gov) - Sep 20, 2016
P1b, N=64, Suspended, Sponsor: Janssen Research & Development, LLC
Phase classification: P2 --> P1 | N=155 --> 221 Recruiting --> Suspended
- ||| duvortuxizumab (MGD011) / MacroGenics
Enrollment open: Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma (clinicaltrials.gov) - Aug 22, 2016
P1b, N=64, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Suspended Not yet recruiting --> Recruiting
- ||| duvortuxizumab (MGD011) / MacroGenics
Phase classification, Enrollment change: A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies (clinicaltrials.gov) - Jul 1, 2016
P2, N=155, Recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Phase classification: P1 --> P2 | N=475 --> 155
- || duvortuxizumab (MGD011) / MacroGenics
Phase classification, Enrollment change: A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies (clinicaltrials.gov) - Jun 18, 2016
P1, N=475, Recruiting, Sponsor: Janssen Research & Development, LLC
Phase classification: P1 --> P2 | N=475 --> 155 Phase classification: P2 --> P1 | N=220 --> 475
- | duvortuxizumab (MGD011) / MacroGenics
Phase classification: Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma (clinicaltrials.gov) - Jun 11, 2016
P1b, N=64, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
Phase classification: P2 --> P1 | N=220 --> 475 Phase classification: P1 --> P1b
- ||| duvortuxizumab (MGD011) / MacroGenics
Phase classification, Enrollment change: A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies (clinicaltrials.gov) - May 27, 2016
P2, N=220, Recruiting, Sponsor: Janssen Research & Development, LLC
Phase classification: P1 --> P1b Phase classification: P1 --> P2 | N=540 --> 220
- | duvortuxizumab (MGD011) / MacroGenics
Phase classification: A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies (clinicaltrials.gov) - May 5, 2016
P1, N=540, Recruiting, Sponsor: Janssen Research & Development, LLC
Phase classification: P1 --> P2 | N=540 --> 220 Phase classification: P2 --> P1
- ||| duvortuxizumab (MGD011) / MacroGenics
New P1 trial: Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma (clinicaltrials.gov) - Apr 19, 2016
P1, N=64, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- ||| duvortuxizumab (MGD011) / MacroGenics
Phase classification, Enrollment change, Trial primary completion date: A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies (clinicaltrials.gov) - Apr 15, 2016
P2, N=540, Recruiting, Sponsor: Janssen Research & Development, LLC
Phase classification: P2 --> P1 Phase classification: P1 --> P2 | N=140 --> 540 | Trial primary completion date: Apr 2017 --> Oct 2017
- | duvortuxizumab (MGD011) / MacroGenics
Phase classification: A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies (clinicaltrials.gov) - Mar 24, 2016
P1, N=140, Recruiting, Sponsor: Janssen Research & Development, LLC
Phase classification: P1 --> P2 | N=140 --> 540 | Trial primary completion date: Apr 2017 --> Oct 2017 Phase classification: P2 --> P1
- | duvortuxizumab (MGD011) / MacroGenics
Phase classification: A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies (clinicaltrials.gov) - Mar 4, 2016
P2, N=140, Recruiting, Sponsor: Janssen Research & Development, LLC
Phase classification: P2 --> P1 Phase classification: P1 --> P2
- ||| duvortuxizumab (MGD011) / MacroGenics
Enrollment open: A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies (clinicaltrials.gov) - Jun 26, 2015
P1, N=140, Recruiting, Sponsor: Janssen Research & Development, LLC
Phase classification: P1 --> P2 Not yet recruiting --> Recruiting
- ||| duvortuxizumab (MGD011) / MacroGenics
New P1 trial: A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies (clinicaltrials.gov) - May 27, 2015
P1, N=140, Not yet recruiting, Sponsor: Janssen Research & Development, LLC